Kiniksa Pharmaceuticals, Ltd. - (KNSA): Price and Financial Metrics
Kiniksa Pharmaceuticals, Ltd. - (KNSA)
Today's Latest Price: $17.95 USD
Updated Feb 18 8:00pm
Add KNSA to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 215 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
KNSA Stock Price Chart More Charts
KNSA Price/Volume Stats
| Current price | $17.95 | 52-week high | $21.50 |
| Prev. close | $17.33 | 52-week low | $5.01 |
| Day low | $17.33 | Volume | 113,400 |
| Day high | $18.15 | Avg. volume | 240,553 |
| 50-day MA | $14.11 | Dividend yield | N/A |
| 200-day MA | $11.71 | Market Cap | 985.06M |
Kiniksa Pharmaceuticals, Ltd. - (KNSA) Company Bio
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda
Top Stories View All
Best & Worst Performing Stock Industries for February 18, 2020
Best & Worst Performing Small Cap Stocks for February 18, 2020
Best & Worst Performing Mid Cap Stocks for February 18, 2020
Best & Worst Performing Large Cap Stocks for February 18, 2020
Best & Worst Performing Mega Cap Stocks for February 18, 2020
View All Top Stories
Loading social stream, please wait...